Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.81)
# 1,857
Out of 4,711 analysts
50
Total ratings
34.69%
Success rate
1.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Buy | $36 → $32 | $26.36 | +21.40% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $30.78 | +62.44% | 6 | Nov 27, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $36 → $45 | $44.78 | +0.49% | 4 | Nov 25, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,137 → $1,126 | $701.85 | +60.43% | 4 | Nov 1, 2024 | |
| KYMR Kymera Therapeutics | Reiterates: Buy | $54 → $53 | $40.66 | +30.35% | 3 | Nov 1, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,000 → $1,033 | $767.76 | +34.55% | 3 | Oct 10, 2024 | |
| ABBV AbbVie | Maintains: Buy | $210 → $215 | $175.58 | +22.45% | 1 | Oct 10, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $54 | $4.23 | +1,176.60% | 1 | Sep 27, 2024 | |
| INCY Incyte | Downgrades: Hold | $83 → $74 | $68.84 | +7.50% | 8 | Sep 18, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Buy | $60 | $41.49 | +44.61% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $4.19 | +258.00% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $340 → $302 | $146.47 | +106.19% | 1 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $19.83 | +81.54% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 | $17.03 | +487.20% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $48.87 | +43.24% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $1.19 | +4,942.02% | 2 | Aug 11, 2023 |
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.36
Upside: +21.40%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $30.78
Upside: +62.44%
Scholar Rock Holding
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $44.78
Upside: +0.49%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $1,137 → $1,126
Current: $701.85
Upside: +60.43%
Kymera Therapeutics
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $40.66
Upside: +30.35%
Eli Lilly
Oct 10, 2024
Maintains: Buy
Price Target: $1,000 → $1,033
Current: $767.76
Upside: +34.55%
AbbVie
Oct 10, 2024
Maintains: Buy
Price Target: $210 → $215
Current: $175.58
Upside: +22.45%
Biomea Fusion
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $4.23
Upside: +1,176.60%
Incyte
Sep 18, 2024
Downgrades: Hold
Price Target: $83 → $74
Current: $68.84
Upside: +7.50%
Protagonist Therapeutics
Sep 9, 2024
Initiates: Buy
Price Target: $60
Current: $41.49
Upside: +44.61%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $4.19
Upside: +258.00%
Aug 5, 2024
Reiterates: Buy
Price Target: $340 → $302
Current: $146.47
Upside: +106.19%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $19.83
Upside: +81.54%
Jun 18, 2024
Maintains: Buy
Price Target: $100
Current: $17.03
Upside: +487.20%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $48.87
Upside: +43.24%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $1.19
Upside: +4,942.02%